GSK3β as a potential regulator in AML: A pan-cancer multi-omics analysis
PLOS One · 31.03.2026 · 21 (3) · e0344994
DOI: 10.1371/journal.pone.0344994 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 31.03.2026. Verfasst von Ruyi Qiu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medi…. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Leukemia, Myeloid, Acute. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province.
Abstract (Originalsprache)
The distinct roles of GSK3 isoforms (GSK3α/β) in tumorigenesis and immune modulation remain poorly characterized across malignancies. We integrated multi-omics data from TCGA, GTEx, and single-cell RNA-seq to analyze GSK3α/β expression patterns in 31 cancers. Functional clustering, survival analysis (Cox regression), immune infiltration, and in vitro validation (AML cell lines treated with CHIR-99021) were performed. Integrated multi-omics analysis of 31 malignancies revealed divergent dysregulation of GSK3 isoforms: GSK3α was upregulated in 19 solid tumors but suppressed in AML, while GSK3β was elevated in 23 cancers and high-risk AML subtypes (FAB-M0/M1, P = 0.0013). GSK3β outperformed GSK3α as a pan-cancer diagnostic biomarker, achieving superior AUC in 9 tumors. Prognostically, high GSK3α predicted poor OS in ACC (HR = 8.80, P = 0.0047) and MESO (HR = 2.75, P < 0.0067), whereas GSK3β independently stratified cytogenetic-risk AML (HR = 4.22, P = 0.007). Immune profiling uncovered isoform-specific TME modulation: GSK3α correlated with protumorigenic immune infiltration (Treg/Th17, r = 0.38), contrasting GSK3β’s broad negative associations with cytotoxic effectors (r = −0.27). Functional validation in AML THP-1 cells demonstrated that the GSK3 inhibitor CHIR-99021 (10 μM) significantly suppressed proliferation, induced apoptosis, and caused S-phase cell cycle arrest, concomitant with downregulation of c-Myc. These findings establish GSK3β as a key regulator of oncogenic programs in AML. This study provides a comprehensive pan-cancer atlas of GSK3 isoform-specific functionality, nominating GSK3β as a high-priority therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang Province, China.
- Department of Laboratory Medicine, Huangyan Hospital of Wenzhou Medical University, Taizhou First People's Hospital, Taizhou, Zhejiang Province, China.
- Department of Pathology, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang Province, China.
ORCID-Profile: Ruyi Qiu, Zhejiong Wang
Förderung
- Natural Science Foundation of Zhejiang Province
Zitieren
APA
Qiu, R., Zhou, Y., Song, S., & Wang, Z. (2026). GSK3β as a potential regulator in AML: A pan-cancer multi-omics analysis. PLOS One, 21(3), e0344994. https://doi.org/10.1371/journal.pone.0344994
Vancouver
Qiu R, Zhou Y, Song S, Wang Z. GSK3β as a potential regulator in AML: A pan-cancer multi-omics analysis. PLOS One. 2026;21(3):e0344994. doi:10.1371/journal.pone.0344994
BibTeX
@article{Qiu2026,
author = {Qiu, Ruyi and Zhou, Yingying and Song, Shuang and Wang, Zhejiong},
title = {GSK3β as a potential regulator in AML: A pan-cancer multi-omics analysis},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {3},
pages = {e0344994},
doi = {10.1371/journal.pone.0344994}
}
EUVIMED